HOME ·

CF PHARMTECH

CF PHARMTECH (02652.HK): ICF004 Phase I First Subject Dosed for ILD
Tags：
CF PHARMTECH02652.HKClinical Trial
2026-09-22
CF PHARMTECH (02652.HK): ICF001 expands indications after implied approval from NMPA, covering four indications including pulmonary fibrosis
Tags：
CF PHARMTECH02652.HKR&D Progress
2026-08-24
CF PHARMTECH (02652.HK) plans to issue in total 21.75 million shares by placement, with estimated net proceeds of HKD 294.81 million
Tags：
CF PHARMTECH02652.HKNewTimeSpace
2026-07-31
CF PHARMTECH(02652.HK) closed 7.26% higher
Tags：
CF PHARMTECH02652.HK
2026-04-28
NewTimeSpace | CF PharmTech (02652.HK) Shares Rebound on R&D Breakthrough; High Valuation Overshadowed by 90%+ Reliance on Single Product
Tags：
CF PHARMTECH02652.HKNewTimeSpace
2026-03-17